good news, page-14

Peter Cook has revealed that the interest of potential Lani partners hinge on securing BARDA funding.

It must bring us to question the value of Lani, when potential partners don't see sufficient value to fund the western clinical trials. It would suggest Biota is not in a strong negotiating position to achieve a favourable Lani deal. The expectations of significant upfront payments and 20%+ royalties appear rather optimistic in this light.

The realisation that Lani is not as valuable/attractive to potential partners as we had been led to believe is what has led to the sharp downward movement, not the financial results for the past half-year.

Cheers